Dr. Jorge R. Beato, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 49
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 338
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
FL license ME0036025
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Palmetto General Hospital Hialeah, FL
- Coral Gables Hospital Coral Gables, FL
Medical groups
- Coral Gables Cardiology Inc (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 338
- Services billed
- 714
- Patients’ average age
- 80
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 409 | 320 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 125 | 122 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 93 | 22 |
| Established patient office or other outpatient visit, 20-29 minutes | 68 | 19 |
| Insertion of needle into vein for collection of blood sample | 25 | 13 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 23 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $300,561 in research payments for these studies, mostly to the institutions running them.
- A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
Boehringer Ingelheim International GmbH - A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219 - A multi-centre, single arm, open-label extension study to evaluate the
GlaxoSmithKline, LLC. - A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2)
Genentech, Inc. - A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1)
Genentech, Inc. - A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/…
Boehringer Ingelheim International GmbH - 17 b-hydroxysteroid dehydrogenase type 13 minimization for the treatme
GlaxoSmithKline, LLC. - A 52-week, randomised, double-blind, placebo-controlled, parallel-grou
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.